Stockreport

Santen Receives UK Approval for Ryjunea® (low-dose atropine 0.1 mg/ml) to Slow Progression of Childhood Myopia

SANTEN PHARM CO UNSP/ADR  (SNPHY) 
NASDAQ:AMEX Investor Relations: santen.com/en/ir
PDF First MHRA-approved low-dose atropine eye drop to slow the progression of myopia (short-sightedness) in children aged 3-14 years with a progression rate of 0.5 D or more [Read more]